Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

[up] Up a level
Number of items: 10.

Carter, Kymberley, Cheung, Wai-Yee, Hutchings, Hayley A., Fegan, Greg, Holland, Gail, Luzio, Steve, Dunseath, Gareth, Hiles, Stephen, Marques-Jones, Susie, Gregory, John W. ORCID: https://orcid.org/0000-0001-5189-3812, Tatovic, Danijela ORCID: https://orcid.org/0000-0002-3879-2686, Taylor, Peter ORCID: https://orcid.org/0000-0002-3436-422X, Bowen-Morris, Jane, Stenson, Rachel, Hanna, Stephanie, Mahmood, Zainab, Yang, Jennie, Williams, Evangelia, Tree, Timothy, Marwaha, Ashish and Dayan, Colin M. ORCID: https://orcid.org/0000-0002-6557-3462 2025. The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT. Efficacy and Mechanism Evaluation 12 (1) , pp. 1-66. 10.3310/fqln7416
file

Wych, Julie, Brunner, Martina, Stenson, Rachel, Chumura, Piotr Jaroslaw, Danne, Thomas, Mander, Adrian Paul ORCID: https://orcid.org/0000-0002-0742-9040, Mathieu, Chantal, Dayan, Colin ORCID: https://orcid.org/0000-0002-6557-3462 and Pieber, Thomas R. 2024. Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial. BMJ Open 14 (11) , e091597. 10.1136/bmjopen-2024-091597
file

Tatovic, Danijela ORCID: https://orcid.org/0000-0002-3879-2686, Marwaha, Ashish, Taylor, Peter ORCID: https://orcid.org/0000-0002-3436-422X, Hanna, Stephanie J., Carter, Kym, Cheung, W. Y., Luzio, Steve, Dunseath, Gareth, Hutchings, Hayley A., Holland, Gail, Hiles, Steve, Fegan, Greg, Williams, Evangelia, Yang, Jennie H. M., Domingo-Vila, Clara, Pollock, Emily, Wadud, Muntaha, Ward-Hartstonge, Kirsten, Marques-Jones, Susie, Bowen-Morris, Jane, Stenson, Rachel, Levings, Megan K., Gregory, John W. ORCID: https://orcid.org/0000-0001-5189-3812, Tree, Timothy I. M., Dayan, Colin ORCID: https://orcid.org/0000-0002-6557-3462, Gevers, Evelien, Kanumakala, Shankar, Nair, Sunil, Gardner, Chris, Ajzensztejn, Michal, Wei, Christina, Mouditis, Chris, Campbell, Fiona, Greening, James, Webb, Emma, Chen, Mimi, Amin, Rakesh, White, Billi, Shetty, Ambika, Bidder, Chris, Conway, Nicholas, Mayo, Amalia, Christakou, Eleni, Sychowska, Kamila, Shahrabi, Yasaman, Robinson, Maximilian, Ahmed, Simi, Dutz, Jan and Cook, Laura 2024. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine 30 , pp. 2657-2666. 10.1038/s41591-024-03115-2
file

Gregory, John W. ORCID: https://orcid.org/0000-0001-5189-3812, Carter, Kymberley, Cheung, Wai Yee, Holland, Gail, Bowen-Morris, Jane, Luzio, Stephen, Dunseath, Gareth, Tree, Timothy, Yang, Jennie Hsiu Mien, Marwaha, Ashish, Alhadj Ali, Mohammad, Bashir, Nadim, Hutchings, Hayley Anne, Fegan, Greg W., Stenson, Rachel, Hiles, Stephen, Marques-Jones, Susie, Brown, Amy, Tatovic, Danijela ORCID: https://orcid.org/0000-0002-3879-2686 and Dayan, Colin ORCID: https://orcid.org/0000-0002-6557-3462 2021. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open 11 (10) , e049595. 10.1136/bmjopen-2021-049595
file

Alhadj Ali, M. ORCID: https://orcid.org/0000-0002-9780-6443, Gee, N.Tze, Howell, A., Stenson, R. and Dayan, C. ORCID: https://orcid.org/0000-0002-6557-3462 2017. Factors influencing effective recruitment to phase 1 interventional trials in new-onset type 1 diabetes: analysis of 12 months referrals to diabetes research centre [Abstract]. Diabetic Medicine 34 (S1) , P122. 10.1111/dme.16_13304

Gillespie, David ORCID: https://orcid.org/0000-0002-6934-2928, Farewell, Daniel ORCID: https://orcid.org/0000-0002-8871-1653, Barrett-Lee, Peter, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Hawthorne, Anthony Barney, Hurt, Christopher ORCID: https://orcid.org/0000-0003-1206-8355, Murray, Nick, Probert, Chris, Stenson, Rachel and Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631 2017. The use of randomisation-based efficacy estimators in non-inferiority trials. Trials 18 (1) , 117. 10.1186/s13063-017-1837-3
file

Alhadj Ali, M. ORCID: https://orcid.org/0000-0002-9780-6443, Bowen-Morris, J., Gee, N. Tze, Stenson, R., Walkey, H., Littlemore, K. and Dayan, C. ORCID: https://orcid.org/0000-0002-6557-3462 2017. Use of a “YouTube” style video clip to raise interest amongst young people with new‐onset Type 1 diabetes in immunotherapy trials [Abstract]. Diabetic Medicine 34 (S1) , P315. 10.1111/dme.24_13304

Gillespie, David ORCID: https://orcid.org/0000-0002-6934-2928, Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631, Farewell, Daniel ORCID: https://orcid.org/0000-0002-8871-1653, Hawthorne, Antony, Hurt, Chris Nicholas ORCID: https://orcid.org/0000-0003-1206-8355, Probert, Chris, Stenson, Rachel, Barrett-Lee, Peter ORCID: https://orcid.org/0000-0002-6246-7357, Casbard, Angela C. ORCID: https://orcid.org/0000-0001-6241-3052 and Murray, Nick 2015. The use of randomisation-based efficacy estimators in non-inferiority trials [Poster Presentation]. Trials 16 (Suppl) , P129. 10.1186/1745-6215-16-S2-P129
file

Gillespie, David ORCID: https://orcid.org/0000-0002-6934-2928, Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631, Farewell, Daniel ORCID: https://orcid.org/0000-0002-8871-1653, Stenson, Rachel, Probert, Christopher and Hawthorne, A. Barney 2014. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflammatory Bowel Diseases 20 (1) , pp. 82-91. 10.1097/01.MIB.0000437500.60546.2a

Hawthorne, A. B., Stenson, Rachel, Gillespie, David ORCID: https://orcid.org/0000-0002-6934-2928, Swarbrick, Edwin T., Dhar, Anjan, Kapur, Kapil C., Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631 and Probert, Chris S. J. 2012. One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Diseases 18 (10) , pp. 1885-1893. 10.1002/ibd.21938

This list was generated on Wed Apr 2 06:29:52 2025 BST.


Maintained by Cardiff University Information Services